JonesTrading Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $44.00

Alto Neuroscience (NYSE:ANRO) had its target price dropped by analysts at JonesTrading from $49.00 to $44.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. JonesTrading’s price objective indicates a potential upside of 104.02% from the company’s previous close.

ANRO has been the topic of a number of other reports. BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Robert W. Baird increased their target price on Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research note on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Trading Down 0.5%

Shares of ANRO stock opened at $21.57 on Thursday. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.17. The company has a market cap of $689.03 million, a PE ratio of -9.89 and a beta of 2.01. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $19.27 and its two-hundred day moving average is $14.80.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Equities analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in Alto Neuroscience during the 1st quarter worth approximately $52,000. Torren Management LLC acquired a new position in Alto Neuroscience in the fourth quarter worth $62,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience during the first quarter worth $67,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares in the last quarter.

Key Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Several brokers reaffirmed buy/outperform views and high upside potential — HC Wainwright kept a Buy and a $50 price target (large upside vs. current price). Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy with a $30 target, signaling continued analyst conviction despite the trial miss. Article Title
• Positive Sentiment: JonesTrading kept a Buy rating while trimming its target from $49 to $44 — still implying substantial upside from current levels. Article Title
• Positive Sentiment: Robert W. Baird cut its target to $38 but left an Outperform rating — another signal that some analysts view the selloff as a buying opportunity. Article Title
• Neutral Sentiment: Wedbush trimmed its target to $21 and moved to a Neutral rating, reflecting a more cautious stance but only a small target cut vs. price. Article Title
• Neutral Sentiment: Company fundamentals: recent quarter slightly beat EPS expectations, Alto has a market cap near $689M, high liquidity metrics (current/quick ratio ~15.7) and high beta (~2.0) — factors that increase volatility but limit near-term solvency concerns.
• Negative Sentiment: Trial failure: Alto’s schizophrenia study missed its primary endpoint; that clinical setback is the primary driver of selling pressure and re-pricing. Article Title
• Negative Sentiment: Market reaction/coverage: multiple headlines highlight a sharp drop and pre-market weakness after the study news, amplifying volatility and headline-driven flows. Article Title
• Negative Sentiment: Sentiment hit from coverage calling the result a “shocking miss,” which can accelerate short-term selling and make recovery dependent on management commentary, further data, or new catalysts. Article Title

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.